UPDATE: Benchmark Company Reiterates Buy Rating, Raises PT on RTI Biologics

In a report published Monday, Benchmark Company reiterated its Buy rating on RTI Biologics

, and slightly raised its price target from $4.50 to $5.00. Benchmark Company noted, “We are increasing our price target to $5.00, from $4.50, to reflect our increasing comfort in RTI's 18-month growth outlook. We anticipate Management will provide expanding visibility to new MAPC and porcine dermis products that could offer upside to our medium term growth outlook. At minimum, we anticipate greater visibility to our robust earnings growth outlook. Relative to our 37% EPS growth forecast next year, we feel our $5.00 price target remains conservative at 17x EPS of $0.24, plus $0.90 per share in cash.” RTI Biologics closed on Friday at $4.54.